Table 5.
Logistic and linear regression models for outcomes associated with passive immunity and ADG in 33 beef calves assisted at birth and medicated with subcutaneous meloxicam (Metacam, 20 mg/mL, 0.5 mg/kg BW, Boehringer Ingelheim, Ingelheim, Germany) or placebo (0.025 mL/kg)
Odds ratio | P–value | |
---|---|---|
Failure to stand by 1 h | ||
Medication group | ||
Placebo | Referent | — |
Meloxicam | 1 | 1.0 |
Ranch | ||
A | Referent | — |
B | 13.2 | 0.003 |
Failure to nurse by 1 h | ||
Medication group | ||
Placebo | Referent | — |
Meloxicam | 0.7 | 1.0 |
Failed transfer of passive immunity | ||
Medication group | ||
Placebo | Referent | — |
Meloxicam | 0.2 | 0.36 |
Route colostrum consumed | ||
Nursed from cow | Referent | — |
Tubed or esophageal fed | 13.6 | 0.01 |
Coefficient (SE) | P-value | |
Serum IgG, g/L | ||
Medication group | ||
Placebo | Referent | — |
Meloxicam | 6.1 (4.4) | 0.176 |
Calving difficulty | ||
Easy | Referent | — |
Difficult | −14.4 (4.6) | 0.004 |
ADG to 7 to 10 d, kg | ||
Medication group | ||
Placebo | Referent | — |
Meloxicam | 0.29 (0.1) | 0.05 |
Ranch | ||
A | Referent | — |
B | 0.4 (0.2) | 0.01 |
Serum IgG concentration, g/L | 0.01 (0.005) | 0.03 |
ADG to weaning, kg | ||
Medication group | ||
Placebo | Referent | — |
Meloxicam | 0.05 (0.05) | 0.3 |
Ranch | ||
A | Referent | — |
B | −0.2 (0.06) | 0.003 |
Treatment for disease | ||
No | Referent | — |
Yes | 0.5 (0.3) | 0.1 |
Treatment for disease by Ranch interaction | −0.3 (0.1) | 0.04 |